tbuckley/cabot-search huggingface dataset:
Down-regulation of Pdcd4 is sufficient to promote colon tumor cell invasion
Authors: Qing Wang, Zhenxiao Sun, Hsin-Sheng Yang
Journal: Cancer Research (2007)

2163  Progression of benign tumor into invasive carcinoma is a major cause of death in the cancer patients. Understanding the mechanism of colorectal cancer invasion/metastasis will improve the treatment for colon cancer patients. Programmedcell death 4 (Pdcd4) is a novel tumor suppressor, which inhibits TPA-induced transformation and tumor phenotype in mouse epidermal JB6 cells. Recently, overexpression of pdcd4 cDNA in invasive colon tumor cell, RKO cell, significantly reduces invasion ability in Matrigel invasion assays and intravasation ability in chicken embryo metastasis assays. In addition, Pdcd4 transgenic mice that overexpress Pdcd4 in the epidermis show significant reductions in DMBA/TPA induced skin papilloma formation, carcinoma incidence, and papilloma-carcinoma conversion frequency. These findings suggest that Pdcd4 suppresses carcinogenesis not only at an early stage (tumor promotion) but also at a late stage (tumor progression) in both cultured cells and transgenic mice. Pdcd4 expression is down-regulated in several types of human cancer including lung, liver, pancreas, and ovary cancers. Most importantly, a higher pdcd4 protein level correlates with a good prognosis in lung cancer patients, suggesting that elevating the expression of Pdcd4 may prolong the survival of patients. However, it is unknown whether down-regulation of Pdcd4 expression is sufficient to promote tumor development.  In this study, we analyzed 86 colon tumor and adjacent normal tissues and found that Pdcd4 expression in colon tumor tissues is down-regulated. In addition, the Pdcd4 protein level in the invasive colon tumor cells is lower than that in the non-invasive colon tumor cells. These findings suggest that Pdcd4 regulates colon tumor progression. To test the role of Pdcd4 in colon tumor progression, we knocked down Pdcd4 expression in non-invasive colon tumor cells by Lentiviral system delivered shRNA. We found that Pdcd4 knock-down triggered fibroblast-like morphological changes and induced cell migration. Moreover, Pdcd4 knock-down cells show increased invasion by Matrigel invasion assay. To investigate the molecular events involved in the down-regulation of Pdcd4 in colon tumor cells, we performed a series of Western blot, immunofluorescent staining and transient transfections analyses. We found that knock-down Pdcd4 expression stimulates the translocation of β-catenin into nuclei and activates β-catenin dependent transcription. These results indicate that knock-down Pdcd4 expression activates Wnt signal pathway. These findings provide an underlying mechanism by which Pdcd4 functions in colorectal tumor invasion, since deregulation of Wnt signaling pathway has been found in the majority of colorectal cancer patients.
Third Party Cytokine-Induced Killer Cells Eliminate Highly Activated T-Cells, Leading to Protect from Murine Lethal Graft-Versus-Host Disease
Authors: Rie Kuroda, Shintaro Mase, Hideaki Maeba, Toshihiro Fujiki, Masaki Fukuda, Raita Araki, Yasuhiro Ikawa, Shoichi Koizumi, Akihiro Yachie, Ryosei Nishimura
Journal: Blood (2016)
Retraction
Authors: Niklas Feldhahn, Ines Schwering, Sanggyu Lee, Maria Wartenberg, Florian Klein, Hui Wang, Guolin Zhou, San Ming Wang, Janet D. Rowley, Jürgen Hescheler, Martin Krönke, Klaus Rajewsky, Ralf Küppers, Markus Müschen
Journal: The Journal of Experimental Medicine (2006)
Presepsin (soluble CD14 subtype) levels in cirrhotic patients with bacterial infections and/or portal hypertension related bleeding presented with or without acute kidney injury
Authors: I.S. Elefsiniotis, S. Tsakiris, G. Barla, A. Tasovasili, I. Stathopoulou, K. Tampouratzi, E. Evangelidou, D. Vrachatis, C. Mavrogiannis
Journal: Journal of Hepatology (2017)
Early limited-stage small cell lung cancer: Sub-group analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial
Authors: A. Salem, L. Ashcroft, A. Dagnault, C. de Metz, M. Hatton, I. Locke, I. Monnet, L. Padovani, F. Blackhall, C. Faivre-Finn
Journal: Annals of Oncology (2017)
NGS-Based Copy Number Analysis in 1,185 Patients with Myeloid Neoplasms
Authors: Ryunosuke Saiki, Yusuke Shiozawa, Tetsuichi Yoshizato, Kenichi Yoshida, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Chiba, Yoshiko Atsuta, Makoto Onizuka, Hidehiro Itonaga, Yoshinobu Kanda, Mikkael A. Sekeres, Kathryn M. Guinta, Shuichi Miyawaki, Tsuyoshi Nakamaki, Shigeru Chiba, Lee-Yung Shih, Yasushi Miyazaki, Satoru Miyano, Hideki Makishima, Jaroslaw P. Maciejewski, Seishi Ogawa
Journal: Blood (2016)
Identification of Twinfilin-1 as a key regulator of cholangiocyte biological response to injury: evidence for a possible role of ageing in the progression of cholangiopathies
Authors: L. Maroni, C. Pinto, D.M. Giordano, S. Saccomanno, C. Rychlicki, L. Trozzi, M.C. Albertini, F. Orlando, E. Melum, J. Banales, A. Benedetti, G.S. Baroni, M. Marzioni
Journal: Journal of Hepatology (2017)
Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody positive subjects
Authors: S. Zandanell, A. Feldman, L. Denkmayr, M. Strasser, S. Ruhaltinger, G. Strebinger, U. Huber-Schönauer, D. Niederseer, L. Stechemesser, B. Paulweber, M. Schranz, C. Datz, E. Aigner
Journal: Journal of Hepatology (2017)
Rising healthcare utilization and cost of chronic hepatitis B: real-world analysis of 44,026 chronic hepatitis B patients and 121,568 matched non-chronic hepatitis B controls in the United States
Authors: J. Lim, M. Nguyen, I. Liou, A.B. Ozbay, L. Moore-Schiltz, G. Dusheiko, S. Gordon
Journal: Journal of Hepatology (2017)
Need for radiological staging in breast cancer patients with axillary micrometastases.
Authors: Celine Montavon, Viola A. Heinzelmann-Schwarz, Uwe Gueth, Marcus Vetter
Journal: Journal of Clinical Oncology (2014)

e12026 Background: Patients with lymph node (LN) positive breast cancer generally receive radiological staging for distant metastases (DM). Whilst this is sensible in advanced stage disease, only 2-3 % of patients with 1-3 positive LNs will have DM. In this study we therefore question the necessity of this staging procedure in patients with axillary micrometastases (pN1mi) and assess the outcome of this specific patient population. Methods: We retrospectively assessed all invasive breast cancer patients who had primary surgery with axillary staging and 1-3 positive LNs (pN1) between 1990 and 2009 at the Women’s University Hospital Basel, Switzerland (n=332). Since 2004, due to international recommendations, sentinel LN biopsies were routinely performed. During the study period we performed a general screening for DM in all patients with LN positive disease. Ethical allowance for this retrospective analysis was granted by the local ethics committee (EKBB to U.G.). Results: In the group of patients with pN1 disease, the detection rate of DM was 2.4%. Out of this patient group, 54 patients (16.3%) showed only micrometastatic axillary involvement. During the sentinel biopsy period a significantly higher rate of micrometastases were found: 1990-2003, n=27/217 (12.4%) vs. 2004-2009, n=27/115 (23.5%), p=0.012. In none of these patients, radiological staging found any evidence for DM. After a long median follow-up time of 71.5 months, nine patients had developed DM and died of breast cancer (16,67 %). Conclusions: Since introduction of sentinel LN biopsies, 25% of patients with pN1 disease presented with only micrometastatic axillary involvement. Due to the fact that only very few of these patients must be expected to have DM at the time of diagnosis (none in our study cohort of 332 patients), we recommend to omit routine radiological staging in these patients due to low risk. This change of practice will reduce unnecessary diagnostic procedures and improve the quality of life of our patients be avoiding unnecessary anxiety.
Metabolic shifts in residual breast cancer drive tumor recurrence
Authors: Kristina M. Havas, Vladislava Milchevskaya, Ksenija Radic, Ashna Alladin, Eleni Kafkia, Marta Garcia, Jens Stolte, Bernd Klaus, Nicole Rotmensz, Toby J. Gibson, Barbara Burwinkel, Andreas Schneeweiss, Giancarlo Pruneri, Kiran R. Patil, Rocio Sotillo, Martin Jechlinger
Journal: Journal of Clinical Investigation (2017)

Tumor recurrence is the leading cause of breast cancer-related death. Recurrences are largely driven by cancer cells that survive therapeutic intervention. This poorly understood population is referred to as minimal residual disease. Here, using mouse models that faithfully recapitulate human disease together with organoid cultures, we have demonstrated that residual cells acquire a transcriptionally distinct state from normal epithelium and primary tumors. Gene expression changes and functional characterization revealed altered lipid metabolism and elevated ROS as hallmarks of the cells that survive tumor regression. These residual cells exhibited increased oxidative DNA damage, potentiating the acquisition of somatic mutations during hormonal-induced expansion of the mammary cell population. Inhibition of either cellular fatty acid synthesis or fatty acid transport into mitochondria reduced cellular ROS levels and DNA damage, linking these features to lipid metabolism. Direct perturbation of these hallmarks in vivo, either by scavenging ROS or by halting the cyclic mammary cell population expansion, attenuated tumor recurrence. Finally, these observations were mirrored in transcriptomic and histological signatures of residual cancer cells from neoadjuvant-treated breast cancer patients. These results highlight the potential of lipid metabolism and ROS as therapeutic targets for reducing tumor recurrence in breast cancer patients.
Value of Immunohistochemistry-Based Direct Visualization for Localization, Lineage Determination and Monitoring of IDH1 p.R132H Mutant Clones in AML
Authors: Habibe Kurt, Carlos E. Bueso-Ramos, Joseph D Khoury, Mark Routbort, Rashmi Kanagal-Shamanna, Jeffrey L. Jorgensen, Courtney D DiNardo, Farhad Ravandi, Hagop M. Kantarjian, Raja Luthra, Jeffrey Medeiros, Keyur Patel
Journal: Blood (2016)
Multicenter prospective randomized controlled trial comparing propranolol, endoscopic band ligation, and combination therapy for the primary prophylaxis variceal bleeding in patients with liver cirrhosis
Authors: Y.S. Seo, M.Y. Kim, H.J. Yim, H.S. Kim, S.G. Kim, S.Y. Park, B.I. Kim, J.Y. Park, H. An, S.K. Baik, Y.S. Kim, W.Y Tak, K.-H. Han, S.H. Um
Journal: Journal of Hepatology (2017)
Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis
Authors: Maya Khalil, Tea Reljic, Jessica El-Asmar, Mehdi Hamadani, Taiga Nishihori, Ernesto Ayala, Ambuj Kumar, Mohamed A Kharfan-Dabaja
Journal: Blood (2016)
Pancreatic insufficiency related to hepatocellular carcinoma treatment: early detection and treatment improves therapeutic adherence
Authors: A. Diaz-Gonzalez, A. Darnell, J. Rimola, E. Belmonte, B. Loreto, L. Neus, A. Forner, G. Iserte, C. Ayuso, F. Feu, J. Bruix, M. Reig
Journal: Journal of Hepatology (2017)
High sustained viral response among hepatitis C virus genotype 3 patients with advanced liver fibrosis - real-world data of HCV elimination program in Georgia
Authors: M. Butsashvili, L. Gvinjilia, G. Kamkamidze, D. Metreveli, S. Dvali, T. Rukhadze, A. Gamkrelidze, M. Nasrullah, J. Morgan, F. Averhoff
Journal: Journal of Hepatology (2017)
A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program
Authors: Elizabeth K. Ely, Stephanie M. Gruss, Elizabeth T. Luman, Edward W. Gregg, Mohammed K. Ali, Kunthea Nhim, Deborah B. Rolka, Ann L. Albright
Journal: Diabetes Care (2017)

To assess participant-level results from the first 4 years of implementation of the National Diabetes Prevention Program (National DPP), a national effort to prevent type 2 diabetes in those at risk through structured lifestyle change programs.
Margaret McCartney: Only data can say if new is better
Authors: Margaret McCartney
Journal: BMJ (2017)

Managing heart failure is often hard work for patients and professionals.Steering between fluid overload and postural hypotension, while keeping the kidneys perfused and quality of life maintained in a life limiting condition, is a difficult and draining business.A new drug, then, would be welcomed, and LCZ696 was described to me as "the next big thing" by a cardiology specialist even before the first trial appeared.With the brand name Entresto, it's a combination of valsartan (an old drug, an angiotensin receptor blocker) and sacubitril (a newer neprilysin inhibitor). 1 It was going to be a bit of a revolution, we were promised.The double blind trial of valsartan-neprilysin versus enalapril in heart failure was published in the New England Journal of Medicine in 2014. 2
NS3 inhibition coupled with potent direct acting antiviral combinations leads to enhanced hepatitis C virus specific immunity in hepatitis C virus-human immunodeficiency virus co-infected patients
Authors: S. Shrivastava, M. Bhatta, H. Ward, R. Lee, E. Rosenthal, H. Masur, S. Kottilil, E.M.P. Wilson
Journal: Journal of Hepatology (2017)
Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting
Authors: Javaid Iqbal, Yao-Jun Zhang, David R. Holmes, Marie-Claude Morice, Michael J. Mack, Arie Pieter Kappetein, Ted Feldman, Elizabeth Stahle, Javier Escaned, Adrian P. Banning, Julian P. Gunn, Antonio Colombo, Ewout W. Steyerberg, Friedrich W. Mohr, Patrick W. Serruys
Journal: Circulation (2015)

Background— There is a paucity of data on the use of optimal medical therapy (OMT) in patients with complex coronary artery disease undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting (CABG) and its long-term prognostic significance. Methods and Results— The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial is a multicenter, randomized, clinical trial of patients (n=1800) with complex coronary disease randomized to revascularization with percutaneous coronary intervention or CABG. Detailed drug history was collected for all patients at discharge and at the 1-month, 6-month, 1-year, 3-year, and 5-year follow-ups. OMT was defined as the combination of at least 1 antiplatelet drug, statin, β-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Five-year clinical outcomes were stratified by OMT and non-OMT. OMT was underused in patients treated with coronary revascularization, especially CABG. OMT was an independent predictor of survival. OMT was associated with a significant reduction in mortality (hazard ratio, 0.64; 95% confidence interval, 0.48–0.85; P =0.002) and composite end point of death/myocardial infarction/stroke (hazard ratio, 0.73; 95% confidence interval, 0.58–0.92; P =0.007) at the 5-year follow-up. The treatment effect with OMT (36% relative reduction in mortality over 5 years) was greater than the treatment effect of revascularization strategy (26% relative reduction in mortality with CABG versus percutaneous coronary intervention over 5 years). On stratified analysis, all the components of OMT were important for reducing adverse outcomes regardless of revascularization strategy. Conclusions— The use of OMT remains low in patients with complex coronary disease requiring coronary intervention with percutaneous coronary intervention and even lower in patients treated with CABG. Lack of OMT is associated with adverse clinical outcomes. Targeted strategies to improve OMT use in postrevascularization patients are warranted. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00114972.
Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine histological images in patients with Non-Alcoholic Fatty Liver Disease
Authors: R. Forlano, J. Maurice, N. Angkathunyakul, E. Goldin, M. Yee, G. Serviddio, N. Giannakeas, A.T. Tzallas, M.G. Tsipouras, R.D. Goldin, M. Thursz, P. Manousou
Journal: Journal of Hepatology (2017)
Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network
Authors: A. Wranke, S. Hardtke, L.M.P. Borzacov, R. Parana, C. Lobato, S. Hamid, E. Ceausu, G.N. Dalekos, M. Rizzetto, A. Turcanu, G. Niro, T. Hayden, M. Abbas, P. Ingiliz, M. Buti, P. Ferenci, T. Vanwolleghem, A. Motoc, Z. Abbas, C. Yurdaydin, M.P. Manns, H. Wedemeyer, B.C. Serrano, M. Wöbse, B. Heidrich, M. Muche, N.K. Gatselis, K. Zachou, A. Smedile, R. Gish, D. Obretin, R. Stern, E. Ho, P. Michielsen, O.D. Valentina, F. Lubna, R. Fontana
Journal: Journal of Hepatology (2017)
The anti-human immunodeficiency virus drug rilpivirine decreases hepatic injury in a nutritional model of non-alcoholic fatty liver disease through activation of the IL6/IL22-STAT3-p53 axis
Authors: A. Martí-Rodrigo, F. Alegre, M. Polo, Á.B. Moragrega, N. Apostolova, J.V. Esplugues, A. Blas-García
Journal: Journal of Hepatology (2017)
Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort
Authors: S. Madonia, V. Calvaruso, R. Filomia, M.R. Cannavò, M. Di Stefano, M. Russello, A. Davì, G. Scifo, R. Volpes, A. Montineri, R. Ficalora, G. Malizia, A. Digiacomo, G. Bertino, G. Alaimo, A. Licata, B. Cacopardo, A. Averna, L. Guarneri, I. Scalisi, P. Colletti, F. Cartabellotta, F. Savalli, M. Cannizzaro, G. Raimondo, A. Craxì, V. Di Marco
Journal: Journal of Hepatology (2017)
Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1
Authors: P. Buggisch, A. Moreno, V. Isakov, L. Backus, D. Ain, P. Ruane, J. Gonzalez, S. Naik, S. Mehta, J. Lee, M. Mertens, M. Natha, K. Kersey, A. Osinusi, K. Zhdanov, J. Berenguer, S. Zeuzem
Journal: Journal of Hepatology (2017)
Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects
Authors: C.H. Nelson, B.J. Kirby, N. Lu, B. McColgan, C.S. Djedjos, R.P. Myers, J. Cuvin, A. Qin, A. Mathias
Journal: Journal of Hepatology (2017)
Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer.
Authors: Nisha Anjali Mohindra, Sheetal Mehta Kircher, Halla Sayed Nimeiri, Al B. Benson, Alfred Rademaker, Erin Alonso, Nicole Blatner, Khashayarsha Khazaie, Mary Frances Mulcahy
Journal: Journal of Clinical Oncology (2015)

e15281 Background: Agents with durable responses are needed for patients with advanced pancreatic cancer (APC). T regulatory cells (Treg) create a protective microenviroment around pancreatic tumor cells that allows for immune evasion and limits the effectiveness of chemotherapy. Ipilimumab, a monoclonal antibody that blocks CTLA-4, downregulates Tregs and activates tumor specific T cells. Ipilimumab produced durable responses and overall survival benefit in metastatic melanoma patients. We report the final results of a dose finding study of gemcitabine and ipilimumab for APC. Methods: Dose limiting toxicity (DLT) was assessed during a 12 week induction cycle consisting of gemcitabine (750-1000 mg/m2) weekly for 7 weeks followed by one week off, then weekly for 3 weeks and ipilimumab (3-10 mg/kg) on weeks 1, 4, 7, and 10. Response was evaluated at 12 weeks by RECIST, mWHO criteria and immune-related response criteria (irRC). If deriving clinical benefit at 12 weeks, subjects continued gemcitabine 3 weeks on with one week off and ipilimumab at the assigned dose every 12 weeks starting at week 22. Results: As of January 1, 2015, 13 subjects with APC were enrolled and evaluable for toxicity. The median age is 64 years (45-83), ECOG PS 0-1, 9 received prior therapy for advanced disease. Two subjects had DLTs at a dose of gemcitabine 1000 mg/m2 and ipilimumab 6 mg/kg (grade 3 hepatotoxicity and grade 3 diarrhea), which exceeded the maximally tolerated dose (MTD). The most frequent adverse events (AEs) were thrombocytopenia (10), leukopenia (9), neutropenia (8), anemia (8), and fatigue (8). Grade 3-4 related AEs occurred in 9 subjects, most commonly neutropenia (6), anemia (4), leukopenia (3), thrombocytopenia (2) and nausea (2). 11 subjects were evaluable for response by RECIST criteria. Partial response was seen in 2 pts (15%) and stable disease in 5 pts (38%), distributed among all cohorts. Conclusions: The MTD is ipilimumab 3 mg/kg with gemcitabine 1000 mg/m2. DLT is immune related hepatotoxicity and diarrhea. The most common toxicities are hematologic. Markers of immune response will be reported. An expansion phase of the combination is ongoing. Clinical trial information: NCT01473940.
A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern Europe
Authors: Petr Winkler, Dzmitry Krupchanka, Tessa Roberts, Lucie Kondratova, Vendula Machů, Cyril Höschl, Norman Sartorius, Robert Van Voren, Oleg Aizberg, Istvan Bitter, Arlinda Cerga-Pashoja, Azra Deljkovic, Naim Fanaj, Arunas Germanavicius, Hristo Hinkov, Aram Hovsepyan, Fuad N Ismayilov, Sladana Strkalj Ivezic, Marek Jarema, Vesna Jordanova, Selma Kukić, Nino Makhashvili, Brigita Novak Šarotar, Oksana Plevachuk, Daria Smirnova, Bogdan Ioan Voinescu, Jelena Vrublevska, Graham Thornicroft
Journal: The Lancet Psychiatry (2017)
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Authors: A.M. Allen, M. Yin, S.K. Venkatesh, T. Mounajjed, T.A. Kellogg, M.L. Kendrick, T.J. McKenzie, K. Glaser, V.S. Shah, R.L. Ehman
Journal: Journal of Hepatology (2017)
Video-Assisted Thoracic Surgery (VATS) lobectomy for non-small cell lung cancer after induction chemotherapy: A propensity score-matched analysis on behalf of the Italian VATS group
Authors: L. Bertolaccini, A. Pardolesi, D. Argnani, J. Brandolini, D. Divisi, A. Bertani, A. Droghetti, A. Gonfiotti, R. Crisci, P. Solli
Journal: Annals of Oncology (2017)
Response to: ‘A reminder of the importance of not losing the forest through the trees in the appraisal of systematic review findings’
Authors: Brian C Focht, Ciaran M Fairman
Journal: British Journal of Sports Medicine (2017)

We thank Neil-Sztramko et al 1 for their interest in our paper2 where they outline concerns they suggest may confound what can be concluded from the findings. We address each of their concerns below. A more detailed response to the authors can be found in the online supplementary file.

Neil-Sztramko et al raise an excellent point regarding the relevance of evaluating if inclusion of multiple papers from larger trials may have meaningfully influenced the percentage of studies we categorised as implementing the resistance training (RT) principles of interest. Accordingly, we recalculated the results after removing papers that represented secondary analyses of larger trials and added the studies they suggested be included. The revised recalculation, involved 29 studies and yielded implementation rates of 72% for …
Tissue-resident lymphocytes: sentinel of the transformed tissue
Authors: Saïda Dadi, Ming O. Li
Journal: Journal for ImmunoTherapy of Cancer (2017)

Tumor cells can be detected and cleared by lymphocytes in a process termed cancer immunosurveillance. However, the contributing cell types had not been fully characterized. Using oncogene-induced murine models of epithelial cancer, a recent study showed that cell transformation triggers expansion of tissue-resident lymphocytes derived from innate, T cell receptor (TCR) αβ and TCRγδ lineages. These type-1-like innate lymphoid cells (ILC1ls) and type 1 innate-like T cells (ILTC1s) share a gene expression program distinct from those of conventional lymphocytes, and exhibit cytolytic activities against tumor cells. Further deciphering such a tumor-elicited immunosurveillance mechanism may 1&nbsp;day be harnessed for novel cancer immunotherapy.